A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids
Clinical trial NCT05653219 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05653219
- Sponsor
- Novartis Pharmaceuticals
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-02-02
- Primary completion
- 2025-06-19
- Enrollment
- 152
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.